China1 Tailwind: Can Neogen’s Battery Chemistry Pay Off for Shareholders?

Neogen Chemicals’ expansion into China+1-linked specialty chemicals and battery materials is a positive long-term opportunity, though it comes with near-term execution and valuation risks.

The company has built a strong position in bromine and lithium chemistry, supplying pharma, agrochemicals and advanced intermediates. As global customers diversify sourcing away from China, Neogen is well placed to benefit from this structural shift, providing a potential avenue for sustained revenue growth beyond cyclical domestic demand. To capture this opportunity, Neogen has significantly expanded capacity across Maharashtra, Gujarat and Hyderabad, while investing heavily in electrolyte solutions and lithium salts for EV batteries. These capital-intensive projects are likely to suppress free cash flow and return ratios initially, but they also create meaningful operating leverage. Higher plant utilisation and long-term customer contracts could significantly improve margins and earnings over time. The principal risk for shareholders is timing. Capacity is being added ahead of demand, and delays in customer approvals, slower adoption of China+1 sourcing, or global pricing pressure could keep ROCE subdued and make the stock appear expensive on near-term earnings. However, successful execution, supported by technology, product quality and regulatory compliance, could help Neogen move further up the specialty chemicals value chain and command premium valuations. Overall, the China+1 opportunity appears more favourable than adverse for long-term shareholders, provided they are comfortable with a capex-driven growth strategy, execution risks and short-term earnings volatility.